Binding of Low Density Lipoprotein to Platelet Apolipoprotein E Receptor 2' results in phosphorylation of p38MAPK by Korporaal, S.J.A. et al.
Binding of Low Density Lipoprotein to Platelet Apolipoprotein E
Receptor 2 Results in Phosphorylation of p38MAPK *
Received for publication, July 2, 2004, and in revised form, September 29, 2004
Published, JBC Papers in Press, September 30, 2004, DOI 10.1074/jbc.M407407200
Suzanne J. A. Korporaal‡§, Ingrid A. M. Relou‡§, Miranda van Eck¶, Vera Strasser,
Martineke Bezemer‡, Gertie Gorter‡, Theo J. C. van Berkel¶, Johannes Nimpf,
Jan-Willem N. Akkerman‡, and Peter J. Lenting‡**
From the ‡Laboratory for Thrombosis and Haemostasis, Department of Haematology, University Medical Center Utrecht
and Institute of Biomembranes, University of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands, the
¶Division of Biopharmaceutics, Leiden Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden University,
P. O. Box 9502, Leiden, 2300 RA, The Netherlands, and the Department of Medical Biochemistry, Division of Molecular
Genetics, Biocenter and University of Vienna, Dr. Bohrgasse 9/2, A-1030 Vienna, Austria
Binding of low density lipoprotein (LDL) to platelets
enhances platelet responsiveness to various aggrega-
tion-inducing agents. However, the identity of the plate-
let surface receptor for LDL is unknown. We have pre-
viously reported that binding of the LDL component
apolipoprotein B100 to platelets induces rapid phospho-
rylation of p38 mitogen-activated protein kinase
(p38MAPK). Here, we show that LDL-dependent activa-
tion of this kinase is inhibited by receptor-associated
protein (RAP), an inhibitor of members of the LDL re-
ceptor family. Confocal microscopy revealed a high de-
gree of co-localization of LDL and a splice variant of the
LDL receptor family member apolipoprotein E recep-
tor-2 (apoER2) at the platelet surface, suggesting that
apoER2 may contribute to LDL-induced platelet signal-
ing. Indeed, LDL was unable to induce p38MAPK activa-
tion in platelets of apoER2-deficient mice. Furthermore,
LDL bound efficiently to soluble apoER2, and the tran-
sient LDL-induced activation of p38MAPK was mimicked
by an anti-apoER2 antibody. Association of LDL to
platelets resulted in tyrosine phosphorylation of
apoER2, a process that was inhibited in the presence of
PP1, an inhibitor of Src-like tyrosine kinases. Moreover,
phosphorylated but not native apoER2 co-precipitated
with the Src family member Fgr. This suggests that ex-
posure of platelets to LDL induces association of
apoER2 to Fgr, a kinase that is able to activate p38MAPK.
In conclusion, our data indicate that apoER2 contrib-
utes to LDL-dependent sensitization of platelets.
Platelets and low density lipoproteins (LDL)1 are key ele-
ments in the development of atherothrombotic complications.
The interplay between both elements is apparent from the
notion that LDL particles markedly enhance the responsive-
ness of platelets to various aggregation-inducing agents (1–4).
These agonists mediate the release of growth factors, vasoac-
tive substances, and chemotactic agents that are known to
stimulate atherosclerotic plaque formation. Sensitization of
platelets by LDL involves the major LDL constituent apoli-
poprotein B100 (apoB100) (5), a 4563 amino acid protein that is
wrapped around the LDL particle (6). LDL particles are recog-
nized by the classical hepatic LDL receptor (LDL-R) through
the apoB100 moiety, and in particular through a region within
the apoB100 protein that is enriched in positively charged
amino acids, the so-called B-site (7). Like LDL, a synthetic
peptide mimicking this B-site associates to the platelet surface
(5). Moreover, this peptide interferes with binding of LDL to
platelets (5), suggesting that both elements share similar bind-
ing sites. This possibility is supported by the observation that
binding of either LDL or the B-site peptide to the platelet
results in a near immediate activation of the intracellular
enzyme p38 mitogen-activated protein kinase (p38MAPK) (5, 8).
Activation of this Ser/Thr kinase is associated with down-
stream phosphorylation and activation of cytosolic phospho-
lipase A2, which leads to the formation of thromboxane A2 (9,
10). Finally, enhanced platelet function occurs via exposure of
the integrin IIb3 and fibrinogen binding (11).
The mechanism by which LDL particles signal to p38MAPK is
yet unclear, but it seems conceivable that it involves a receptor-
dependent pathway. The finding that the signaling pathway is
initiated by the apoB100 component of LDL may point to the
involvement of an LDL-binding receptor. However, platelets
are known to lack the classical LDL-R as well as LDL receptor-
related protein-1 (LRP1) (12, 13). Recently, a splice variant of
apolipoprotein E receptor-2 (apoER2) has been identified in
platelets and megakaryocytic cell lines (14). ApoER2, which is
also known as LDL receptor-related protein-8, is a member of
the LDL receptor family, and is mainly expressed in brain,
testes, and vascular cells but not in the liver (15, 16). Its
structure is most closely related to the LDL-R and VLDL-R
(17). However, transcriptional analysis has revealed that mul-
tiple alternative splicing variants of apoER2 exist (18, 19), one
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of which, apoER2, is present in platelets (14). Platelet apoER2
mRNA encodes a 130-kDa protein, which consists of a single
ligand-binding domain that comprises four complement type A
repeats (compared with seven repeats in full-length apoER2),
an epidermal growth factor-like homology region, an O-linked
sugar domain, and a single transmembrane domain that con-
nects the extracellular region to the cytoplasmic tail.
Several studies have shown the ability of apoER2 to bind and
internalize apoE-containing lipid vesicles (14, 15). However,
the contribution of apoER2 to the general lipid metabolism is
probably limited, since mice genetically deficient for apoER2 do
not suffer from increased plasma lipoprotein levels (20). Be-
cause also the endocytosis rate of apoER2 is almost 20-fold
lower compared with LRP1 (21), it seems conceivable that
apoER2 serves an alternative physiological function as well.
Indeed, there is firm support for a role of apoER2 in cellular
signaling processes. For example, apoER2 has been reported to
contribute to the neuronal signaling pathway that governs the
layering of the developing cortex (20). In this process, apoER2
functions as a receptor for the signaling molecule reelin, and
transmits the reelin signal to the intracellular adaptor protein
disabled-1, which associates to the cytoplasmic tail of apoER2
(20, 22, 23, 24). This tail contains an XNPXY sequence (where
 is a hydrophobic amino acid residue), which may function as
a potential binding site for phosphotyrosine binding domains of
signaling molecules, including disabled-1. In addition, the cy-
toplasmic region of apoER2 contains three proline-rich areas
that correspond to the consensus sequence (PXXP) for Src
homology-3 recognition (14). All of these motifs that potentially
link apoER2 to various signaling pathways are also present in
the platelet variant of this receptor (14).
In the present study, we investigated whether apoER2 has
the potential to transmit the LDL signal to intracellular sig-
naling components, with particular reference to p38MAPK. We
found that LDL bound efficiently to soluble apoER2 and that
an anti-apoER2 antibody was similar to LDL particles in acti-
vating p38MAPK. Furthermore, the absence of apoER2 in plate-
lets was associated with a lack of LDL-dependent p38MAPK
activation, while inhibition of ligand binding to apoER2 by the
39 kDa receptor-associated protein (RAP) interfered with LDL-
dependent phosphorylation of p38MAPK. Finally, incubation of
platelets with LDL particles resulted in a rapid tyrosine phos-
phorylation of apoER2. This process was mediated by Src-like
kinases and allowed the association with the signaling mole-
cule Fgr. In view of our data, we propose that apoER2 serves
a critical role in the LDL-initiated signaling pathway that
governs platelets with increased sensitivity toward its aggre-
gation-inducing agents.
EXPERIMENTAL PROCEDURES
Mice—Wild-type C57Bl/6 mice and mice genetically deficient for the
LDL receptor (LDL-R/), CD36 (CD36/), scavenger receptor BI (SR-
BI/), and scavenger receptor A (SR-A/) were used in this study.
C57Bl/6 mice were obtained from Charles River (Maastricht, The Neth-
erlands). Mice genetically deficient for apoER2 have been described
previously (20). Homozygous LDL-R/ mice, originally generated by
Ishibashi et al. (25), were obtained from the Jackson Laboratory (Bar
Harbor, ME) as mating pairs, and bred at the Gorlaeus Laboratories
(Leiden, The Netherlands). CD36/ mice were kindly provided by Dr.
M. Febbraio (Department of Medicine, Weill Medical College of Cornell
University, New York) (26), SR-BI/ mice by Dr. M. Krieger (Depart-
ment of Biology, Massachusetts Institute of Technology, Cambridge,
MA) (27), and Mex-4 SR-A/ mice by Dr. T. Kodama (Department of
Molecular Biology and Medicine, University of Tokyo, Tokyo, Japan)
(28). All mice were backcrossed at least 4 generations to the C57Bl/6
background. Mice had unlimited access to water and regular chow diet,
containing 4.3% (w/w) fat with no added cholesterol (RM3, Special Diet
Services, Witham, UK). All experimental protocols were approved by
the local ethics committees for animal experiments.
Materials—Nonfat dry milk was obtained fromNutricia (Zoetermeer,
the Netherlands). Bovine serum albumin (BSA), a monoclonal antibody
against -actinin, protease inhibitor mixture, peroxidase-conjugated
anti-goat IgG, and sodium vanadate (NaVO3) were obtained from
Sigma. Prostacyclin (PGI2) was from Cayman Chemical (Ann Arbor,
MI). Protein G-Sepharose was obtained from Amersham Biosciences.
PP1 was from Alexis Biochemicals (San Diego, CA). Renaissance chemi-
luminescence Western blot reagent was from PerkinElmer Life Sci-
ences. Polyclonal antibodies against p38MAPK and dual phosphorylated
p38MAPK (phosphoplus p38MAPK), and horseradish peroxidase-labeled
anti-rabbit IgG were from New England Biolabs (Beverly, MA). An
antibody against the ligand binding domain of apoER2 (anti-apoER2
antibody 186) has been described previously (24). A polyclonal antibody
directed against c-Fgr, a polyclonal antibody directed against Src ki-
nases, and a goat polyclonal antibody directed against the ectodomain
of apoER2 were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-LDL-R monoclonal antibody was obtained from Oncogene
Research Products (Boston, MA). Anti-phosphotyrosine monoclonal an-
tibody 4G10 was from Upstate Biotechnology (Bucks, UK). The anti-
human apoB100 monoclonal antibody 2D8 used for confocal microscopy
was obtained from the University of Ottawa Heart Institute (Ontario,
Canada), and has been described previously (29). The anti-apoB100
antibody used in the solid phase assay was from BiosPacific (Em-
eryville, CA). Fibrinogen -chain derived dodecapeptide HHLG-
GAKQAGDV (400–411) was kindly provided by the Department of
Biochemistry at the University of Utrecht (Utrecht, The Netherlands).
SDZ-GPI-562 (GPI-562) was a kind gift of Dr. H. G. Zerwes (Novartis
Pharmaceuticals, Basel, Switzerland).
Proteins—RAP fused to glutathione S-transferase (GST-RAP) (30)
was prepared as described previously (31). The peptide RL-
TRKRGLKLA (Mr  1311) designated B-site peptide, represents the
receptor binding domain within apoB100. The peptide was synthesized
by standard solid phase peptide synthesis and purified by C18 reverse-
phase chromatography (HPLC, Genosphere biotechnologies, Paris,
France). The purity of the peptides was 99% as determined by HPLC,
and the molecular weights were verified by matrix-assisted laser de-
sorption mass spectrometry by the manufacturer. Preparation of recom-
binant murine soluble apoER2 (s-apoER2) fused to mannose-binding
protein was performed as described (32).
Lipoprotein Isolation—Lipoproteins were isolated as described be-
fore (11). In short, fresh, non-frozen plasma from 3 healthy subjects
each containing less than 100 mg of lipoprotein(a)/liter was pooled, and
LDL (density range 1.019–1.063 kg/liter) was isolated by sequential
flotation in a Beckman L-80 ultracentrifuge (33). Centrifugations (175,
000  g, 20 h, 10 °C) were carried out in the presence of NaN3 and
EDTA. The quality of these preparations has been described (11). Li-
poproteins were stored at 4 °C under nitrogen for not longer than 14
days and before each experiment dialyzed overnight against 104 vol-
umes 150 mmol/liter NaCl. ApoB100 and lipoprotein(a) concentrations
were measured using the Behring Nephelometer 100. The concentra-
tion of LDL was expressed as grams of apoB100 protein/liter.
Platelet Isolation—Freshly drawn venous blood from healthy volun-
teers was collected with informed consent into 0.1 volume 130 mmol/
liter trisodium citrate. The donors claimed not to have taken any
medication during 2 weeks prior to blood collection. Platelet-rich
plasma (PRP) was prepared by centrifugation (200  g, 15 min, 22 °C).
Gel-filtered platelets (GFPs) were isolated by gel filtration through
Sepharose 2B equilibrated in Ca2-free Tyrode’s solution (137 mmol/
liter NaCl, 2.68 mmol/liter KCl, 0.42 mmol/liter NaH2PO4, 1.7 mmol/
liter MgCl2, and 11.9 mmol/liter NaHCO3, pH 7.25) containing 0.2%
BSA and 5 mmol/liter glucose. GFPs were adjusted to a final count of
2  1011 platelets/liter.
For the isolation of murine platelets, mice were anesthetized by
subcutaneous injection of a mixture of xylazine (5 mg/ml), ketamine (40
mg/liter), and atropine (0.05 mg/ml), and blood was subsequently col-
lected into 0.1 volume of 130 mmol/liter trisodium citrate and 0.1
volume of ACD buffer (2.5 g of trisodium citrate, 1.5 g of citric acid, and
2 g of D-glucose in 100 ml of distilled water) by heart puncture. PRP was
obtained by centrifugation (87 g, 15 min, 20 °C). The remainder of the
blood was diluted with Hepes-Tyrode buffer (145 mmol/liter NaCl, 5
mmol/liter KCl, 0.5 mmol/liter Na2HPO4, 1 mmol/liter MgSO4, 10
mmol/liter Hepes, 5 mmol/liter D-glucose, pH 6.5), and 0.1 volume of
ACD buffer and centrifuged again (87  g, 15 min, 20 °C). PRP samples
were pooled, and platelets were isolated from PRP by centrifugation
(350 g, 15 min, 20 °C) in the presence of 0.1 volume of ACD buffer and
resuspended in Hepes-Tyrode buffer (pH 6.5). PGI2 was added to a final
concentration of 10 ng/ml, and the washing procedure was repeated
once. The platelet pellet was resuspended in Hepes-Tyrode buffer (pH
7.2). Platelet count was adjusted to 1  1011 platelets/liter.
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p38MAPK Assay—Human GFPs or washed murine platelets were
incubated at 37 °C with LDL, anti-apoER2 antibody 186 or anti-LDL-R
antibody as indicated. After incubation, 100-l aliquots were mixed
(1:10 v/v) with cold lysis buffer consisting of 10% (v/v) Nonidet P-40, 5%
(w/v) octylglucoside, 50 mmol/liter EDTA, 1% (w/v) SDS supplemented
with 5 mmol/liter NaVO3 and 10% (v/v) protease inhibitor mixture and
subsequently taken up in Laemmli sample buffer. Samples were heated
prior to SDS-polyacrylamide gel electrophoresis (12%). Proteins were
electrophoretically transferred (1 h, 100 volts) to a nitrocellulose mem-
brane using a mini-protean system (Bio-Rad). The blots were blocked in
5% (w/v) nonfat dry milk, 0.1% (v/v) Tween 20 in phosphate-buffered
saline (PBS) (1 h, 4 °C) and incubated with the phosphoplus p38MAPK
(recognizing p38MAPK phosphorylated at Thr180 and Tyr182) or p38MAPK
antibody, which recognizes both phosphorylated and non-phosphory-
lated isoforms (1:2000 (v/v) in 1% (w/v) nonfat dry milk, 0.1% (v/v)
Tween in PBS, 16 h, 4 °C). Both antibodies are raised against residues
171–186 of human p38MAPK. After washing, the membranes were incu-
bated with horseradish peroxidase-labeled anti-rabbit (1:2000 (v/v), 1 h,
4 °C) and p38MAPK was visualized using the enhanced chemilumines-
cence reaction. For semi-quantitative determination of the amount of
dual phosphorylated or total p38MAPK, the density of the bands was
analyzed using ImageQuant software (Molecular Dynamics).
Solid Phase Binding Assay—Microtiter plates were incubated with
Tris-buffered saline (TBS), 2 mmol/liter CaCl2 containing 10 g/ml of
s-apoER2 (16 h, 4 °C). After blocking (1 h, 22 °C) in blocking solution
(2% BSA in TBS, 2mmol/liter CaCl2, 0.05% (v/v) Tween), wells were
incubated with different concentrations of human LDL diluted in block-
ing solution in the presence or absence of 10 mmol/liter EDTA. Bound
LDL was detected by anti-apoB antibody (diluted 1:500 in blocking
solution) followed by peroxidase-conjugated secondary antibody (di-
luted 1:40,000 in blocking solution). All incubations were carried out at
room temperature for 1 h. For the color reaction, a solution of 0.1
mol/liter sodium acetate, pH 6.0 containing 0.1 mg/ml of 3,3,5,5-
tetramethylbenzidine and 10 mmol/liter H2O2 was used. The reaction
was stopped after 5 min by the addition of 0.3 mol/liter H2SO4, and
bound secondary antibody was photometrically quantified at 450 nm.
Surface Plasmon Resonance Analysis—Surface plasmon resonance
(SPR) binding experiments were performed using a Biacore2000 bio-
sensor system. A biotinylated peptide corresponding to the apoB100
B-site was immobilized at a density of 239 fmol/mm2. A control channel
was prepared by the immobilization of a biotinylated irrelevant mono-
clonal antibody. Binding of s-apoER2 was corrected for binding to this
control channel (less than 2%). SPR analysis was performed in 150
mmol/liter NaCl, 2.5 mmol/liter CaCl2, 0.005% (v/v) Tween-20, 25
mmol/liter Hepes (pH 7.4) at 25 °C with a flow rate of 5 l/min. Regen-
eration of the sensor chip surface was performed by incubating with 10
mmol/liter taurodeoxycholic acid, 100 mmol/liter Tris (pH 9.0) for 2 min.
Data were analyzed as described previously (34).
ApoER2 Tyrosine Phosphorylation—Human GFPs were incubated
at 37 °C with LDL or B-site peptide as indicated, mixed with ice-cold
lysis buffer (1:10 v/v) as described above and subsequently taken up in
Laemmli sample buffer. ApoER2 was precipitated using a goat poly-
clonal antibody directed against apoER2 (1 g/ml) and protein
G-Sepharose for 3 h at 4 °C. Precipitates were washed three times with
lysis buffer (containing 1 mmol/liter phenylmethylsulfonyl fluoride, 1
mmol/liter NaVO3, and 1 g/ml leupeptin) and taken up in non-reduc-
ing Laemmli sample buffer. Samples were analyzed by SDS-PAGE and
Western blotting. Tyrosine phosphorylation of apoER2 was visualized
by incubation with 4G10, an antibody directed against phosphorylated
tyrosine residues (0.5 g/ml, 16 h, 4 °C), followed by incubation with
peroxidase-linked anti-mouse IgG (1:5000 (v/v), 1 h, 4 °C), and the
enhanced chemiluminescence reaction. As a control for equal lane load-
ing, the blots were stripped and incubated with a monoclonal anti--
actinin antibody (1:5000 (v/v), 16 h, 4 °C), followed by incubation with
peroxidase-linked anti-mouse IgG (1:5000 (v/v), 1 h, 4 °C). For semi-
quantitative determination of apoER2 phosphorylation, the density of
the bands was analyzed using ImageQuant software. Complex forma-
tion between apoER2 and Src family tyrosine kinases was monitored
by immunoprecipitation of apoER2 from lysates of LDL-stimulated
platelets, followed by Western blotting with a polyclonal antibody
against c-Fgr (0.4 g/ml, 16 h, 4 °C), and a subsequent incubation with
horseradish peroxidase-labeled anti-rabbit IgG (1:10,000 (v/v), 1 h,
4 °C).
Immunofluorescence Studies—Human GFPs were incubated at 37 °C
with LDL (1.0 g/liter) in the presence or absence of GST-RAP (0.3
mol/liter, 10 min). Then, the platelets were applied to coverslips after
fixation with 1% (v/v) paraformaldehyde, washed with PBS, blocked for
10 min with PBS containing 1% (w/v) BSA and 0.1% (v/v) glycine (pH
7.4), and incubated with the monoclonal anti-apoB100 2D8 (5) and the
goat polyclonal anti-apoER2 antibody. Afterward, the coverslips were
incubated with a tetramethylrhodamine B isothiocyanate (TRITC)-la-
beled anti-mouse antibody (BD Biosciences, San Jose, CA) and a fluo-
rescein isothiocyanate (FITC)-labeled anti-goat antibody, diluted 1:20
(v/v) in PBS for 45 min at 37 °C, followed by washing with PBS.
Coverslips were embedded in Mowiol and analyzed by confocal laser
microscopy on a Leica confocal laser microscope.
Statistics—Data are expressed as means  S.E. with number of
observations n and were analyzed with the Student’s t test for unpaired
observations. Differences were considered significant at p  0.05.
RESULTS
LDL-dependent Activation of p38MAPK in the Absence of
LDL-R, CD36, SR-BI, or SR-A—LDL-particles are recognized
by the classical hepatic LDL-R through the apoB100 moiety (7).
The scavenger receptors SR-BI and CD36 also bind LDL, in
contrast to SR-A that only binds LDL after modification (35).
To investigate the contribution of these receptors to LDL-de-
pendent platelet sensitization, platelets were obtained from
wild-type C57Bl/6 mice and mice that were genetically defi-
cient for one of the following receptors: LDL-R, CD36, SR-BI, or
SR-A. These platelets were incubated with freshly purified
LDL (1 g/liter) for 5 min, and activation of p38MAPK was sub-
sequently assessed by comparing the binding of antibodies
directed against dual-phosphorylated p38MAPK to the binding
of antibodies recognizing total p38MAPK. In the absence of LDL,
low levels of phosphorylated p38MAPK relative to the total
amount of the kinase were present in platelets from wild-type
as well as the various knockout mice (Fig. 1). As expected, a
substantial increase in phosphorylation was observed upon
incubation of wild-type platelets with LDL. Moreover, an in-
crease in phosphorylation of p38MAPK was also observed when
platelets obtained from the various knockout mice were incu-
bated with LDL (Fig. 1). Thus, at least in mice, LDL-mediated
p38MAPK activation is a process that may occur independently
of LDL-R, CD36, SR-BI, and SR-A, suggesting that other LDL-
binding receptors are involved.
LDL-induced Platelet p38MAPK Activation Requires the Pres-
ence of ApoER2—Ligand binding to members of the LDL re-
ceptor family is blocked in the presence of RAP. To study
whether LDL-induced platelet signaling involves a RAP-sensi-
tive receptor, LDL-dependent phosphorylation of p38MAPK in
human platelets was determined in the absence and presence
of GST-RAP (0.15–0.45 mol/liter). As shown in Fig. 2A, sim-
ilar amounts of p38MAPK were present in all samples, and the
kinase was efficiently phosphorylated upon incubation of the
human platelets with LDL (1 g/liter for 1 min). The presence of
GST-RAP, however, was associated with a dose-dependent de-
crease in p38MAPK phosphorylation, with over 70% inhibition at
0.45 M GST-RAP (Fig. 2B). GST alone (0.45 M) failed to affect
LDL-induced p38MAPK phosphorylation (Fig. 2B, inset). This
FIG. 1. LDL-induced p38MAPK phosphorylation may proceed
independently of LDL-R, CD36, SRBI, and SR-A. Platelets from
wild-type C57Bl/6 mice and mice genetically deficient for the LDL-R
(LDL-R/), CD36 (CD36/), SR-BI (SR-BI/), and SR-A (SR-A/)
were stimulated with LDL (1.0 g/liter, 1 min, 37 °C). Samples were
drawn and centrifuged (30 s, 9000  g, 22 °C) and resuspended in
sample buffer. Samples were split, and dual phosphorylated p38MAPK
was identified in one part by SDS-PAGE and Western blotting using a
phosphospecific anti-p38MAPK polyclonal antibody (upper panel). An-
other part was analyzed for equal loading by detecting total p38MAPK
using an antibody against p38MAPK (lower panel).
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indicates that LDL-dependent activation of p38MAPK is medi-
ated by a RAP-sensitive receptor, only one of which has been
reported to be present in platelets: apoER2 (14). As such,
apoER2 is a candidate receptor for LDL particles at the plate-
let surface. To test the contribution of this receptor, p38MAPK
activation was monitored using platelets obtained from
apoER2-deficient mice. As shown in Fig. 2C, LDL was unable to
induce the phosphorylation of p38MAPK in the absence of
apoER2. Thus, these data show that apoER2 is an essential
link in the process of LDL-dependent p38MAPK activation
in platelets.
ApoER2 and LDL Co-localization on the Platelet Surface—As
apoER2 is indispensable for LDL-dependent phosphorylation
of p38MAPK, we further examined whether LDL particles in-
deed are able to interact with this receptor. Therefore, we first
analyzed the location of apoER2 and of platelet-bound LDL
employing confocal immunofluorescence microscopy analysis.
Platelets were incubated with LDL (1 g/liter) in the presence or
absence of GST-RAP (0.3 mol/liter). By using antibodies di-
rected against apoER2 and the LDL constituent apoB100, it
was found that both proteins were selectively present at the
platelet surface (Fig. 3). Merging of both images suggested a
high degree of co-localization of apoB100 and apoER2, indicat-
ing that LDL may bind to or in close proximity of apoER2.
Furthermore, in the presence of GST-RAP only minor amounts
of apoB100 were detectable at the platelet surface, demonstrat-
ing that GST-RAP interferes with LDL binding to the
platelet surface.
Interaction between s-ApoER2 and LDL—Since LDL and
ApoER2 appear to co-localize at the platelet surface, direct
binding studies were performed to address the interaction be-
tween both components. First, various concentrations of LDL
(0–10 g/ml) were incubated with immobilized murine
ApoER2 (1 g/well), and bound LDL was detected employing
an anti-apoB100 directed antibody. A dose-dependent and sat-
urable binding isotherm was observed, with half-maximal
binding at 0.28 g/ml LDL (Fig. 4A). Little, if any, binding was
observed in the presence of EDTA. In a complementary ap-
proach, the interaction between this receptor and the LDL
constituent apoB100 was examined by SPR analysis. To this
end, various concentrations of murine s-apoER2 (50–300
nmol/liter) were perfused over a biotinylated peptide corre-
sponding to the B-site of apoB100 immobilized on a streptavi-
din sensorchip (239 fmol/mm2). Association of soluble apoER2
FIG. 2. LDL-induced p38MAPK phos-
phorylation in the presence of GST-
RAP and in platelets lacking
apoER2. A, platelets were incubated
with GST-RAP (0.15, 0.30, and 0.45 M,
10 min, 37 °C) prior to incubation with
LDL (1 g/liter, 1 min, 37 °C). p38MAPK
phosphorylation was determined as de-
scribed in the legend to Fig. 1. B, blots
were semi-quantified, and the data were
expressed as percentage of the p38MAPK
phosphorylation in the absence of GST-
RAP (open symbol). Inset, platelets were
incubated with GST alone (0.45 mol/li-
ter, 10 min, 37 °C) prior to stimulation
with LDL. Data are expressed as
means  S.E., n  4. C, platelets from
apoER2-deficient mice were stimulated
with LDL (1 g/liter, 1 min, 37 °C), and
analyzed for p38MAPK phosphorylation as
described in the legend to Fig. 1.
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to the peptide was found to be dose-dependent as the highest
response was observed for the highest concentration (Fig. 4B),
whereas binding to the control channel was less than 2% com-
pared with the peptide-coated channel (not shown). Analysis of
the sensorgrams revealed that the association and dissociation
curves were best fitted to a model describing the interaction
with a single class of binding sites. The apparent dissociation
and association rate constants were calculated to be 1.21 
0.12  103 s1 and 2.96  0.33  104 M1 s1, resulting in an
apparent affinity constant of 41 nmol/liter. Hence, the soluble
form of apoER2 constitutes a binding site for LDL, and more
specifically, the ligand-binding region of the LDL constituent
apoB100.
An Anti-ApoER2 Antibody and LDL Are Similar in Activa-
tion of p38MAPK—To further assess the contribution of apoER2
to the activation of p38MAPK, human platelets were incubated
with anti-apoER2 antibody 186 (1:1000 (v/v) (24)). This anti-
body has previously been reported to induce dimerization of
ApoER2, and does not cross-react with other members of the
LDL receptor family (24). As a control, p38MAPK phosphoryla-
tion was determined similarly after incubation of platelets with
LDL (1 g/liter) or in the presence of an anti-LDL-R antibody at
the indicated concentrations. As expected, the anti-LDL-R an-
tibody was unable to induce p38MAPK activation (Fig. 5C),
whereas the presence of LDL was associated with a rapid
increase in the amount of phosphorylated p38MAPK with a
maximum at 1 min (Fig. 5A). This rapid increase was followed
by a gradual decline to baseline levels of phosphorylated
p38MAPK in the following 10 min. A similar time-dependent
pattern was detected when platelets were incubated with anti-
apoER2 antibody 186, with maximal phosphorylation of
p38MAPK observed after 1 min (Fig. 5B). This suggests that
ligand binding to and/or dimerization of apoER2 is associated
with a rapid activation of p38MAPK.
LDL-dependent Phosphorylation of Platelet ApoER2—LDL
receptor-related proteins have been implicated in various sig-
naling events, and participation in signaling processes may be
associated with intracellular phosphorylation of these recep-
tors. We therefore addressed the possibility that association of
LDL particles to the platelet surface results in phosphorylation
of apoER2. Human platelets were incubated with LDL (1
g/liter), and at various time intervals apoER2 was withdrawn
by immunoprecipitation employing a polyclonal anti-apoER2
antibody. Samples were analyzed for the presence of phospho-
rylated tyrosine residues within apoER2 using 4G10, an anti-
body that recognizes tyrosine-phosphorylated proteins. Gel-
loading was monitored employing an antibody directed against
-actinin, a protein that co-precipitated in a nonspecific man-
ner. In non-LDL exposed platelets minor amounts of tyrosine-
phosphorylated apoER2 could be detected (Fig. 6A). However,
incubation of platelets with LDL particles resulted in a marked
increase in tyrosine phosphorylation of apoER2, a process that
appeared to be maximal after 30 s. Prolonged incubations re-
sulted in a gradual decay of phosphorylated apoER2, although
after 20 min its levels were still above basal levels (Fig. 6A).
Phosphorylation of apoER2 also proved to be dependent on the
concentration of LDL (Fig. 6B). Since the synthetic peptide
corresponding to the B-site of the LDL component apoB100
induces p38MAPK activation (5), we further tested whether this
peptide induced tyrosine phosphorylation of platelet apoER2.
Indeed, incubation of platelets with this peptide was associated
with phosphorylation of apoER2 to a similar extent as com-
pared with LDL (Fig. 6C). Previously, it has been suggested
that the integrin IIb3 serves as a receptor for LDL on plate-
lets (36, 37). However, tyrosine phosphorylation of apoER2 by
LDL remained unaffected in the presence of the integrin IIb3
inhibitors, fibrinogen -chain-derived dodecapeptide (400–
411) and GPI-562 (Fig. 6D). Thus, both the synthetic apoB100
B-site peptide and native LDL particles induce reversible phos-
phorylation of the platelet surface receptor apoER2 in a man-
ner that is independent of integrin IIb3.
Recruitment of Src Kinases upon LDL Binding to ApoER2—
Several tyrosine kinases may mediate LDL-dependent tyrosine
FIG. 3. Co-localization of LDL with apoER2 on the platelet
surface. LDL-stimulated platelets were incubated with TRITC-labeled
monoclonal anti-apoB100 2D8 (red, left panel) and apoER2-FITC
(green, middle panel) as described under “Experimental Procedures”
with and without preincubation with GST-RAP (0.30 mol/liter, 10
min) as indicated. The right panel shows a merged picture in which
co-localization of apoER2 and LDL can be visualized (yellow).
FIG. 4. Interaction between recombinant murine s-apoER2
and LDL. A, microtiter plates were coated with 10 g/ml s-apoER2.
After incubation with the indicated amounts of LDL in the presence or
absence of 10 mmol/liter EDTA, bound LDL was detected with anti-
apoB100 and peroxidase-conjugated anti-goat antibodies as described
under “Experimental Procedures.” A450 represents optical density at
450 nm. B, various concentrations of soluble murine apoER2 (50–300
nmol/liter) were perfused over a biotinylated peptide corresponding to
the B-site of apoB100, which was immobilized onto a streptavidin-
sensor chip at a density of 239 fmol/mm2. Perfusion was allowed for 2
min in 150 mmol/liter NaCl, 2.5 mmol/liter CaCl2, 0.005% (v/v) Tween-
20, 25 mmol/liter Hepes (pH 7.4) at 25 °C, after which dissociation was
initiated by perfusion with buffer alone. Binding was corrected for
binding to a control channel (biotinylated irrelevant monoclonal anti-
body), which was less than 2% of binding to the peptide-coated channel.
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phosphorylation of the cytoplasmic tail of platelet ApoER2. It
has been reported by others that phosphorylation of LRP1 in
fibroblastic cells involves the Src family of tyrosine kinases
(38). In addition, we have previously shown that the Src kinase
inhibitor PP1 interferes with LDL-dependent phosphorylation
of p38MAPK (5). Therefore, PP1 was used to examine the role of
the Src kinase family in the phosphorylation of apoER2 by
LDL. In the absence of LDL and PP1, low levels of phosphoryl-
ated apoER2 were present, whereas a marked increase was
observed upon incubation with LDL (Fig. 7A). However, prein-
cubation of platelets with PP1 (1, 5 and 10 mol/liter) reduced
LDL-induced apoER2 tyrosine phosphorylation up to 80%
(Fig. 7A). This strongly suggests that Src-like tyrosine kinases
play a dominant role in the phosphorylation of the apoER2
cytoplasmic tail. To identify the Src-like kinase that contrib-
utes to this process, LDL-treated platelets were used for co-
immunoprecipitation experiments employing a polyclonal anti-
apoER2 antibody. In preliminary experiments, analysis of the
precipitates with polyclonal antibodies that recognize multiple
members of the Src family, including Fyn, c-Src, Yes, and Fgr,
revealed a band migrating with an apparent molecular mass of
55 kDa (data not shown). As the molecular mass of Fgr corre-
sponds to 55 kDa, the precipitates were re-examined employing
an antibody specifically directed against Fgr. Minor association
of Fgr to apoER2 could be detected in platelets that were not
exposed to LDL (Fig. 7B). In contrast, incubation with LDL
resulted in a transient association of Fgr to apoER2 with
maximal co-precipitation of Fgr at 1–2 min. Thus, association
of LDL with the platelet surface leads to association of apoER2
with the Src kinase Fgr.
DISCUSSION
Association between platelets and LDL particles is believed
to result in the formation of hyperreactive platelets, enhancing
the risk for thrombotic complications and atherosclerotic
plaque formation. Several studies have been directed to the
identification of LDL-induced signaling pathways that are re-
sponsible for the increased responsiveness of platelets to its
various agonists (8, 39, 40). Although much insight has been
gained in these signaling pathways, the identification of the
platelet surface receptor(s) mediating LDL binding has re-
mained inconclusive. Previously, the platelet integrin IIb3
has been suggested to serve as a receptor for LDL, as inferred
from ligand blotting and immunofluorescence studies (36, 37).
However, specific antibodies directed against integrin IIb3
proved unable to inhibit the binding of LDL to platelets. Fur-
thermore, similar binding characteristics were found with
platelets obtained from controls and Glanzmann’s thrombaste-
nia patients, who lack integrin IIb3 (11). Thus, the involve-
ment of IIb3 in LDL binding at the platelet surface is incon-
clusive (11, 41), leaving the possibility that other receptors are
involved in LDL-induced platelet signaling.
In order to identify the platelet receptor for LDL-particles,
we focused on LDL-dependent activation of the Ser/Thr kinase
p38MAPK (8). Phosphorylation of this kinase was not affected by
the genetic deletion of various receptors (LDL-R, CD36, SR-BI,
and SR-A) (Fig. 1). This could be compatible with a mechanism
of redundancy that compensates for the absence of one of these
receptors. Alternatively, LDL-dependent p38MAPK activation
may be mediated independently of these receptors. Indeed,
phosphorylation of p38MAPK was almost completely inhibited in
the presence of GST-RAP, pointing to the involvement of a
FIG. 5. Anti-apoER2 antibody-induced phosphorylation of p38MAPK. Human platelets were incubated with LDL (1.0 g/liter, A), anti-
apoER2 antibody 186 (1:1000; B) or an anti-LDL-R antibody (0.1–10 g/ml, C) at 37 °C for the indicated time periods. p38MAPK phosphorylation
was determined as described in the legend to Fig. 1. The graphs show the semi-quantification of dual-phosphorylated p38MAPK from the blots. Data
were expressed as percentage of the p38MAPK phosphorylation after 1 min of incubation (open symbol). Means  S.E., n  3.
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member of the LDL receptor family in LDL-dependent activa-
tion of p38MAPK (Fig. 2). This possibility is supported by our
observations that (i) the absence of apoER2 in platelets of mice
genetically deficient for this receptor resulted in a lack of
LDL-dependent p38MAPK activation (Fig. 2C); (ii) the LDL-
component apoB100 co-localized at the platelet surface with
the platelet receptor apoER2 (Fig. 3A); (iii) GST-RAP inter-
fered with binding of LDL to the platelet surface (Fig. 3B); (iv)
soluble apoER2 interacted efficiently with LDL and the
apoB100-derived B-site peptide (Fig. 4); (v) LDL particles and
an anti-apoER2 antibody were similar in mediating p38MAPK
activation (Fig. 5); and (vi) apoER2 was rapidly phosphoryl-
FIG. 6. Tyrosine phosphorylation of apoER2 by LDL. A, platelets were incubated with LDL (1 g/liter, 37 °C). At the indicated time points,
apoER2 was immunoprecipitated from platelet lysates and tyrosine phosphorylation was detected by SDS-PAGE and Western blotting with 4G10,
an antibody directed against tyrosine-phosphorylated proteins (upper lane). After stripping, the membranes were reprobed with a monoclonal
antibody directed against -actinin as a control for equal lane loading (lower panel). The graph shows the semi-quantification of tyrosine
phosphorylation of apoER2 relative to the density of the bands representing -actinin. Data were expressed as percentage of the density after 1
min of incubation with LDL (open symbol; means  S.E., n  3). B, platelets were incubated with the indicated concentrations of LDL (1 min,
37 °C), and tyrosine phosphorylation of apoER2 was monitored as described above. Data were expressed as percentage of the density after
incubation with 1 g/liter LDL (open symbol, means  S.E., n  3). C, platelets were incubated with LDL (1 g/liter, 1 min, 37 °C) or B-site peptide
(100 mol/liter, 1 min, 37 °C). Tyrosine phosphorylation of apoER2 was determined as described above. D, platelets were incubated with the
fibrinogen 400–411 peptide (100 mol/liter, 2 min) or the IIb3 blocker GPI-562 (10 nmol/liter, 1 min) prior to incubation with LDL (1 g/liter,
1 min, 37 °C). ApoER2 tyrosine phosphorylation was detected as described. Data were expressed as percentage of apoER2 tyrosine phosphoryl-
ation in the absence of the blockers of ligand binding to integrin IIb3. (Means  S.E., n  3).
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ated upon the incubation of platelets with LDL particles or
with a peptide corresponding to the B-site of the LDL constit-
uent apoB100 (Fig. 6).
The finding that apoER2 serves as a receptor for apoB100-
containing LDL particles may seem unexpected in view of the
report by Kim et al. (16), who observed only minimal binding of
125I-labeled LDL and VLDL to CHO cells expressing full-length
apoER2. In contrast, efficient binding of apoE-rich -VLDL
particles was observed. It should be mentioned, however, that
in those experiments the lipoprotein concentrations did not
exceed 5 mg/liter, which is far below the physiological LDL
plasma concentration (normal range: 0.6 to 1 g/liter) that is
used in our experiments. Of note, the binding isotherm of LDL
particles to immobilized purified s-apoER2 indicates satura-
tion of the receptor at LDL concentrations below 0.01 g/liter
(Fig. 4A), while LDL concentrations of 0.1–0.3 g/liter are suf-
ficient to induce p38MAPK activation (8). This suggests that
platelet apoER2 would be saturated in normal humans, con-
sidering the physiological levels of 0.6–1 g/liter LDL.
Whereas binding of LDL to apoER2 appears to be mediated
by the apoB100 moiety, binding of -VLDL to apoER2 involves
the apoE component of these lipoprotein particles. Interest-
ingly, incubation of platelets with full-length apoE or synthetic
peptides corresponding to the Arg/Lys-rich sequence of apoE
resulted in a decrease in ADP-induced platelet aggregation, a
process that could be inhibited by RAP (14). Apparently,
apoB100 and apoE seem to have different upstream effects
upon binding to apoER2 in that apoB100 governs platelets an
increased response toward agonists, whereas apoE has the
opposite effect. In this regard, the LDL component apoB100
acts in a similar fashion as dimeric 2-glycoprotein I, which
was recently shown to enhance platelet deposition to collagen
and thrombus size via interaction with apoER2 (42). Thus,
different ligands may initiate different effects through the
same receptor. This conclusion becomes even more intriguing
given the observation that the effects of apoE, apoB100 and
dimeric 2-glycoprotein I can be neutralized by GST-RAP (this
study and Refs. 14 and 42). In principle, GST-RAP should be
considered as a ligand for apoER2, as it shares its interactive
region within the receptor with the other ligands. One possi-
bility that may explain these different responses may be re-
lated to ligand-dependent association of apoER2 with other
cell surface receptors. For instance, LDL-dependent activation
of p38MAPK in platelets is followed by a de-activation step of
this kinase that is mediated by platelet endothelial cell adhe-
sion molecule-1 (PECAM-1) (43). The mechanism underlying
the molecular cross talk between apoER2 and PECAM-1 re-
mains to be elucidated, but the possibility exists that both
receptors meet at the platelet surface in an LDL-dependent
manner. It should be noted in this respect that in preliminary
co-immunoprecipitation experiments no association between
apoER2 and PECAM-1 could be observed upon incubation
with LDL (data not shown).
Incubation of platelets with LDL resulted in the tyrosine
phosphorylation of apoER2, a process that was inhibited in the
presence of the Src kinase inhibitor PP1. This suggests that
apoER2 phosphorylation is mainly dependent on kinases of
the Src family (Fig. 7). ApoER2 phosphorylation coincided
with association to the Src kinase Fgr (Fig. 7). Thus, ligand
binding may facilitate the interaction with Fgr, which in turn
might phosphorylate the receptor. Alternatively, the receptor
may become phosphorylated upon ligand binding by a so far
unidentified Src kinase, which subsequently results in associ-
ation to the signaling molecule Fgr. This kinase has the poten-
tial to act as an activator of p38MAPK in neutrophils (44). It
seems conceivable that Fgr may serve a similar role in plate-
lets. Fgr also mediates the activation of p125 focal adhesion
kinase (FAK) (39). Indeed, incubation of platelets with LDL
particles results in a prompt activation of FAK (39). A similar
pattern of FAK phosphorylation was observed upon incubation
of platelets with anti-apoER2 antibody 186 (data not shown).
Apparently, distinct pathways can be initiated upon ligation
of apoER2.
In conclusion, our study strongly suggests that ApoER2may
act as a receptor for LDL at the platelet surface. Furthermore,
we demonstrate that LDL binding to platelets results in phos-
phorylation of apoER2, and this step appears to be critical to
activate further signaling cascades. Thus, apoER2 serves a so
far unrecognized role in the pre-activation of platelets, and may
therefore be used as a target for the development of therapeutic
strategies aiming to reduce platelet hyperreactivity. Interest-
ingly, a polymorphism within the apoER2 gene has recently
been reported to be associated with the development of Alzhei-
mer disease (45). It would be of interest to investigate whether
this polymorphism or others predispose to thrombotic compli-
cations or display a protective effect.
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